Bioequivalence Study of Pimavanserin 34 mg Capsule

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

January 17, 2024

Study Completion Date

March 9, 2024

Conditions

Parkinson Disease Psychosis

Interventions

DRUG

Pimavanserin 34 mg

1 capsule of Pimavanserin Capsule 34mg

DRUG

NUPLAZID 34 MG Oral Capsule

1 capsule of Pimavanserin Capsule 34mg

Trial Locations (1)

Raptim Research Pvt. Ltd.,, Navi Mumbai

All Listed Sponsors

lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06450184 - Bioequivalence Study of Pimavanserin 34 mg Capsule | Biotech Hunter | Biotech Hunter